Lymphoid neoplasia: The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: A novel lymphomagenic feed-forward loop

Blood

Volumn 122, Issue 26, 2013, Pages 4220-4229

  Psathas, James N ^a   Doonan, Patrick J ^b   Raman, Pichai ^a   Freedman, Bruce D ^b   Minn, Andy J ^c   Thomas Tikhonenko, Andrei ^a,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LINKER PROTEIN; B LYMPHOCYTE RECEPTOR; CALCIUM ION; CD22 PROTEIN; CELL PROTEIN; FCGR 2 B PROTEIN; IMMUNORECEPTOR TYROSINE INHIBITORY MOTIF PROTEIN; MICRORNA; MICRORNA 17 92; MYC PROTEIN; PHOSPHATASE; PROTEIN KINASE SYK; TUMOR PROTEIN; UNCLASSIFIED DRUG; BANK1 PROTEIN, HUMAN; CALCIUM; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; FC RECEPTOR; FCGR2B PROTEIN, HUMAN; FCRL4 PROTEIN, HUMAN; MEMBRANE PROTEIN; MIRN17-92 MICRORNA, HUMAN; MYC PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; MIRN17 92 MICRORNA, HUMAN;

ARTICLE; CALCIUM TRANSPORT; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOID CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; CELL LINE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CALCIUM; CELL LINE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEMBRANE PROTEINS; MICRORNAS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, FC; RECEPTORS, IGG; SIALIC ACID BINDING IG-LIKE LECTIN 2; SIGNAL TRANSDUCTION;

EID: 84894618098     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-473090     Document Type: Article

References (53)

1. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008;22(20):2755- 2766.
2. Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56-67.
3. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68-79.
4. Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131(1):18-32.
5. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):839-843. (Pubitemid 40839736)
6. Lin CH, Jackson AL, Guo J, Linsley PS, Eisenman RN. Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J. 2009;28(20):3157-3170.
7. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50.
8. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9): 1060-1065. (Pubitemid 44325933)
9. Zhao H, Kalota A, Jin S, Gewirtz AM. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood. 2009;113(3):505-516.
10. Chung EY, Dews M, Cozma D, et al. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther. 2008;7(11):1758-1764.
11. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550. (Pubitemid 41528093)
12. Montes-Moreno S, Martinez N, Sanchez-Espiridión B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118(4): 1034-1040.
13. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22): 2313-2323.
14. Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22(4):547-560.
15. Pajic A, Spitkovsky D, Christoph B, et al. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000;87(6):787-793. (Pubitemid 30660555)
16. Creighton CJ, Nagaraja AK, Hanash SM, Matzuk MM, Gunaratne PH. A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA. 2008;14(11):2290-2296.
17. Fu C, Turck CW, Kurosaki T, Chan AC. BLNK: a central linker protein in B cell activation. Immunity. 1998;9(1):93-103. (Pubitemid 28361298)
18. Adachi T, Wakabayashi C, Nakayama T, Yakura H, Tsubata T. CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol. 2000;164(3): 1223-1229. (Pubitemid 30067233)
19. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol. 2005;17(3):290-297. (Pubitemid 40692664)
20. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature. 1994;368(6466):70-73. (Pubitemid 24073879)
21. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood. 2002; 99(8):2662-2669. (Pubitemid 34525350)
22. Baba Y, Kurosaki T. Impact of Ca21 signaling on B cell function. Trends Immunol. 2011;32(12): 589-594.
23. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol. 2006;6(4):283-294.
24. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785-789. (Pubitemid 26004411)
25. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol. 2006;16(4):288-302. (Pubitemid 44311043)
26. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest. 2012;122(6): 2257-2266.
27. Isnardi I, Bruhns P, Bismuth G, Fridman WH, Däeron M. The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcgammaRIIB and is mandatory for negative regulation of B cell activation. Immunol Lett. 2006;104(1-2):156-165. (Pubitemid 43330722)
28. Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem. 2000;275(23):17420-17427. (Pubitemid 30430779)
29. Scharenberg AM, El-Hillal O, Fruman DA, et al. Phosphatidylinositol-3,4, 5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 1998;17(7): 1961-1972. (Pubitemid 28154526)
30. Aman MJ, Lamkin TD, Okada H, Kurosaki T, Ravichandran KS. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J Biol Chem. 1998;273(51):33922-33928. (Pubitemid 29008855)
31. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405-414. (Pubitemid 351405110)
32. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009; 113(2):396-402.
33. Jin HY, Oda H, Lai M, et al. MicroRNA-17;92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J. 2013;32(17):2377-2391.
34. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5): 1851-1861. (Pubitemid 40731764)
35. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511. (Pubitemid 30082188)
36. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-Blymphoblastic leukemia and B-cell lymphoma cells. Oncogene. 2006;25(37):5180-5186. (Pubitemid 44285987)
37. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008;28(7):2167-2174. (Pubitemid 351429964)
38. Mu P, Han YC, Betel D, et al. Genetic dissection of the miR-17;92 cluster of microRNAs in Mycinduced B-cell lymphomas. Genes Dev. 2009; 23(24):2806-2811.
39. Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839-2849.
40. Gupta N, Scharenberg AM, Fruman DA, Cantley LC, Kinet JP, Long EO. The SH2 domain-containing inositol 59-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. J Biol Chem. 1999;274(11): 7489-7494.
41. Sohn HW, Krueger PD, Davis RS, Pierce SK. FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood. 2011;118(24):6332-6341.
42. Otipoby KL, Draves KE, Clark EA. CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem. 2001;276(47):44315-44322.
43. Takata M, Sabe H, Hata A, et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca21 mobilization through distinct pathways. EMBO J. 1994;13(6):1341-1349.
44. Bolland S, Pearse RN, Kurosaki T, Ravetch JV. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity. 1998;8(4):509-516. (Pubitemid 28196804)
45. Fluckiger AC, Li Z, Kato RM, et al. Btk/Tec kinases regulate sustained increases in intracellular Ca21 following B-cell receptor activation. EMBO J. 1998;17(7):1973-1985. (Pubitemid 28154527)
46. Cozma D, Yu D, Hodawadekar S, et al. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest. 2007;117(9):2602-2610. (Pubitemid 47494361)
47. Shaffer AL III, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565-610.
48. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol. 2008; 6(6):e152.
49. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-120.
50. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 1998;92(1): 234-240. (Pubitemid 28303198)
51. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520-13525.
52. Yasuda T, Sanjo H, Pagès G, et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity. 2008;28(4):499-508.
53. Grumont RJ, Strasser A, Gerondakis S. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol Cell. 2002; 10(6):1283-1294. (Pubitemid 36050871)